The rise of Viagra and its influence on the pharmaceutical landscape presents a intricate question for shareholders. While the early sales statistics were impressive, the patent has ended, leading to a deluge of generic alternatives that are eroding profit. In addition, the sector is facing challenges related to demographic trends and changing heal